Details

Project TitleIDENTIFICATION AND CHARACTERIZATION OF THE POTEMPINS-A NEW FAMILY OF PROTEASE INHIBITORS (17016)
Track Code17016
Short Description
Abstract

IDENTIFICATION AND CHARACTERIZATION OF THE POTEMPINS-A NEW FAMILY OF PROTEASE INHIBITORS (17016)

     

Features and Benefits Summary

  • Discovery of six (6) unique protease inhibibitors called Potempins

  • May address a major causative factor of common diseases, protese activity
  • Ability to mutate Protempins to inhibit other proteases
  • May be used to create specific, structure-based drub therapies for cancers, periodontitis, human matrix metalloproteinaded (MMP's), and other pathogens

 *This Technology is available for licensing, further development, or industrial partnering*

    

Market Opportunities

MMP’s, cancer, and other pathogens which utilize proteases are widespread. Current treatments targeting protease activity have less selectivity than this technology and are generally unable to be manipulated to produce therapies for a wider range of diseases. The Potempins discovered may have the ability to overcome these limitations because Potempins are more specific than other inhibitors, cost less and are easily producible, should have a lower risk of side effects than current inhibitors, and the structure could be used as a scaffold which could lead to development of inhibitors for a variety of other proteases. These factors could be effective in both diagnostics and treatment of common diseases.

       

Technology   

Potempins are gene sequences upstream of a protease that bind to a specific C-terminus on the protease and inhibit protease activity. Proteases aid in the breakdown of proteins into peptide chains and amino acids and have been linked as  major causative agents in diseases like MMP’s such as chronic obstructive pulmonary disease, asthma, and pneumonia, as well as cancers, periodontitis, and other pathogens where proteases are a crucial virulence factor. The structure of the Potempins alone and in complex with the specific proteases has revealed new mechanisms of inhibition at the atomic level. Understanding the structure of the Potempins should allow for novel, structure-based, and effective drug therapies of the diseases listed above. With further development this technology may enable Potempins to be mutated to inhibit a broader spectrum of diseases and also be less prone to breakdown through proteolysis.

     

Technology Status

  • IP Status: Patent Pending
  • Fields of Use Available: All

    

Researchers:

  • Dr. Jan Potempa

  • Miroslaw Ksiazek

  • Danuta Mizgalska

 
TagsNone
 
Posted DateJul 14, 2017 1:10 PM